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Abstract. The observation that live Mycobacterium leprae on entry into macrophages from
lepromatous leprosy patients reduced the number of EA rosetting macrophages, was extended 
to macrophages from Swiss white mice also. Further, the fact that dead Mycobacterium leprae
do not bring about such a change in macrophages from mice, allowed us to develop this into
a bacterial viability testing system. Thus drug treated macrophages in the presence of
Mycobacterium leprae showed normal rosetting ability if Mycobacterium leprae are inactivated 
by the drug, but showed reduced level of rosetting when bacteria were not susceptible to the 
drug. It was shown that a drug like dapsone, does act on Mycobacterium leprae based on its 
permeability, quantity available inside the macrophages and inhibition of its action by Para 
amino benzoic acid. The inactivation of Mycobacterium leprae by sulphone and rifampicin was 
also proved by the flourescence diacetate method, which showed poorly viable bacteria after 
exposure to drugs. Thus it has been possible to develop a rapid drug screening method for 
testing the activity of unknown compound against Mycobacterium leprae. 
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Introduction
 
With the advent of drug resistance to sulphone (dapsone di-(4-aminophenyl)-sulphone,
DDS) and recently to rifampicin, two accepted drugs for leprosy, there is a need for
identifying new compounds with activity against Mycobacterium leprae. Rapid in vitro
screening methods are basic requirement for expanded intense drug development work.
Such methods are then supplemented with in vivo test systems. The efforts towards
identifying new compounds with activity against M. leprae have been insignificant, 
partly due to lack of rapid drug screening systems. The mouse foot pad method 
developed by Shepard (1960) as being adopted for routine screening work (Shepard,
1976; Rees, 1964) is time consuming. There are few in vitro techniques that have been
described recently (Ambrose et al., 1978; Nath et al., 1982; Prasad et al., 1981; Vithala et
al., 1983; Nair and Mahadevan, 1984).
We describe here, the utility of a method which uses the membrane changes induced in
mice macrophages by live M. leprae, which leads one to distinguish the dead or
 
 
Abbreviations used: DDS, Dapsone (di-4-aminophenyl)-sulphone; MEM, minimul essential medium; EA,
erythrocyte-amboceptor; PABA, p-amino benzoic acid; FDA, fluorescein diacetate; EB, Ethidium Bromide.
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inactivated M. leprae from live ones. Such an observation was made and was
convincingly demonstrated by Birdi et al. (1983). Birdi et al. (1984) also described how
this method could be adopted as a drug screening system using human macrophages.
This communication provides further data for the usefulness of this method.
 
 
Materials and methods
 
Mycobacterium leprae was obtained from lepromatous tissue of bacillary positive,
treated or untreated patients. Bacilli were prepared as per the method of Ambrose et al.
(1974). Such isolated bacilli were acid-fast stainable and free from other contaminating 
bacteria. These did not grow in normal mycobacteriological media. The bacilli were 
counted and 5 × 106 bacilli were added to each Leighton tube containing macrophage
cultures. M. leprae were also obtained from infected armadillo tissue, supplied by Dr. E. 
Storrs, Florida, USA. Such armadillo-derived bacteria were used as a source of drug
sensitive bacteria to standardise the method of drug testing.
 
 
Macrophage cultures
 
Macrophages from Swiss white mice (random bred) were obtained from the peritoneal
cavity following injection of 5 ml of Eagle's minimal essential medium + 20%
inactivated human serum (AB blood group) into the peritoneal cavity, after killing the
animal by cervical dislocation. The peritoneal fluid was collected after agitating the
cavity and 0·7 ml of the fluid was added to each presterilised Leighton tube. The
macrophages obtained from the peritoneal fluid adhered to the coverslip placed inside
the Leighton tube. The medium was changed every 24 h and after 3 days of such
culturing, esterase positive, phagocytic cells were predominantly distributed as a 
uniform layer in the coverslip inside the petridish. There were no contaminating 
neutrophils and non adherent lymphocytes were not present in any significant numbers.
All these steps were done under sterile conditions. 
Seventy two hours after distribution of macrophage, the drug dapsone (Burroughs
Wellcome Co., India) or rifampicin (Sigma Chemical Co., USA) was added along with
the medium. The drug was washed off after 72 h exposure, following which M. leprae 
were fed to the macrophage cultures. The M. leprae were phagocytosed by the
macrophages and were allowed to interact with the drug inside the macrophage
for 72 h. 
In the final step the macrophages were washed with minimul essential medium
(MEM) to remove any external bacilli and then were subjected to erythrocyte-
amboceptor (EA) rosetting following the method described by Birdi et al. (1983). 
 
 
p -Amino benzoic acid reversal of DDS effect 
 
To show that DDS does enter the macrophages and its action is blocked by its well
known modulator p-amino benzoic acid (PABA) the following experiment was done.
The macrophage culture from the peritoneum of Swiss white mice was cultured and 
after 72 h of culturing it was exposed to drug DDS and PABA. The compounds were 
allowed to enter the macrophage for another 72 h following which a wash with MEM
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was given and M. leprae was added. The M. leprae inside the macrophage were allowed
to interact with the compounds for further 72 h. Following the incubation period the
macrophages were washed with MEM to remove excess bacilli and were then subjected
to EA rosetting. 
 
 
Estimation of DDS inside the macrophages
 
The macrophages grown in vitro for 72 h, were treated as described above with the drug 
dapsone (DDS) following which they were harvested by scarping them with a rubber
policeman. The macrophages were then washed three times with saline so as to get rid
off extra cellular DDS. The count of the macrophages was taken in a haemocytometer
after suspending the macrophages in 1 ml saline. 
The macrophages were then lysed by subjecting them to 8 cycles of freeze-thawing. 
Redistilled ethyl acetate (6 ml) (checked for fluorescence quenching) was added to the
lysate in the presence of 0·5 ml 10 Ν NaOH. The mixture was vortexed to facilitate the
extraction of DDS from lysate to ethylacetate. After separation of the solvent and
aqueous phase (20 min), the ethylacetate phase was aspirated out into another tube with 
a pasteur pippette. To the ethylacetate phase 0·5 g of NaCl was added to remove off any 
water molecules carried during the extraction. The ethyl acetate phase was then allowed 
to separate from the NaCl which sedimented at the bottom. The ethylacetate phase was 
transferred to another tube and then checked for fluorescence using a spectroflourim- 
eter (SFM23-Kontron) which had already been standardised to ng levels of DDS, with a 
sensitivity upto 2 ng/ml. The wave length settings were 285 nm for excitation and 
350 nm for emmission. There was always a control culture of macrophages which had 
not been exposed to the drug to compare with the macrophage culture which was 
exposed to the drug. The results were computed as follows to eliminate the background 
fluorescence of macrophage itself (Peters et al., 1981). 
DDS (in ng)/million macrophages is concentration that causes an absorption level of 
1 million macrophages exposed to drug minus absorption level of 1 million macrop- 
hages not exposed to drug. The quantitation of the drug was determined from a 
standard curve of fluorescence absorption determined for various DDS standard
concentrations. 
 
Determination of viability of M. leprae within macrophages
 
The method used was the fluorescein diacetate (FDA)/ethidium bromide (EB) (Both 
from Sigma Chemical Co., USA) staining of M. leprae (Kvach et al., 1982 as modified
in our laboratory by Nalini, R., Alaka, B. and Mahadevan, P. R., Personal
communications). 
One set of coverslips with adherent macrophages was processed in the manner
described above with drug and bacilli following which they were checked for viability.
The coverslips on the day of termination were rinsed in MEM to wash off the excess 
of bacilli and placed over a drop of the staining solution (20 µg of FDA and 20 µg EB in 
5 ml of phosphate buffered saline). This was incubated for 29 min in the dark. The 
coverslip was sealed with nail polish to prevent evaporation and observed under 
incident fluorescent ultra-violet light using Carl Zeiss fluorescence microscope at a
magnification of 400.
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A total number of 200 macrophages were counted and the number of macrophages
with green bacilli (denoting live M. leprae) were calculated. The total number of  
macrophages with bacteria were estimated by determining their level with acid fast 
bacteria. The viability is then indicated in the number of macrophages showing green
fluorescencing bacteria to the total number of acid fast bacteria containing the
macrophages.
 
 
Results 
 
 
The entry of the drug DDS into the macrophages was clearly demonstrable by an
estimation of the level of DDS in purified macrophages. The internal concentration of
DDS increased with increasing level of DDS outside the cells (table 1) and it has been
possible to calculate the DDS concentration/106 macrophages.
 
Table 1. DDS uptake by macrophages when exposed to various levels
of the drug . 
 
 
The ability of macrophages from the peritoneal cavity of mice to reveal the Fc 
receptors as monitored by EA rosetting is clearly reduced in the presence of 
phagocytosed live M. leprae (table 2). If however the bacteria were killed or inactivated 
before phagocytosis then the rosetting ability is the same as the control. Since
M. leprae are susceptible to DDS, the drug treated macrophages show rosetting ability 
as good as the control, indicating that the drug has inactivated the phagocytosed
Μ. leprae (table 2). The data presented in table 3 show a similar observations using
rifampicin at a concentration of 5 µg/Leighton tube.
To demonstrate that the action of the drug on M. leprae is a true feature, an 
experiment was done with various concentrations of DDS so as to decide the level at 
which M. leprae was inactivated. Data presented on table 4 showed that at concentra- 
tions below 20 ng/ml in the medium, the bacteria inside the macrophages were not 
inactivated, and thus the control level of EA rosetting ability of the macrophages is not 
restored. Thus a clear concentration dependence was demonstrable.
PABA a known inhibitor of sulphone could reverse the effect of DDS on M. leprae in
those macrophages that were given both DDS and PABA (table 5). A degree of
antagonism has been thus demonstrated. 
The drug exposed M. leprae that were inactivated and was responsible to show the
normal level of EA rosetting of the macrophages, could also be shown to be nonviable
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Table 2. Per cent EA rosetting macrophages in presence of armadillo derived M. leprae
with and without exposure to dapsone. 
 
Control: M. leprae added culture significant Ρ < 0·05 Μ. leprae only: Drug + M. leprae
significant Ρ < 0·05.
 
Table 3. Per cent EA rosetting macrophages in presence of armadillo derived M. leprae with and without
exposure to rifampicin.
 
P value A – C < 0·05 Significant 
Ρ value D – C < 0·05 Significant 
 
 
by the fluorescent staining method. The data presented in table 6 clearly show that on
exposure of M. leprae to a level 100 ng (0·1 µg/ml) of DDS caused the M. leprae to
become nonviable; since such drug treated macrophages showed reduced number of
macrophages with green fluorescent bacteria; but showed acid fast stainable bacteria in 
much great numbers. The drug untreated macrophages containing viable Μ. Leprae
were seen as green bacteria fluorescing in higher number of macrophages and
comparable well with macrophages containing acid fast bacteria. Similar results were
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Table 4. Per cent of macrophage exhibiting EA rosetting in presence of M. leprae and exposed to various
concentration of DDS.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each value is an average of 4 experiments with each concentration of the drug added. 
Α–B Ρ < 0·05 significant. 
A–C P < 0·05 –do– 
A–D Ρ < 0·05 significant upto 15 ng only.
Α –Ε P > 0·05 not significant.
A –D P < 0·05 significant above 15 ng only.
 
 
Table 5.  Effect of PABA in relation to DDS action on M. leprae.
 
Dosage DDS –1 µg/tube –1·42 µg/ml.
PABA – 0·5 mg/tube – 0·70 mg/ml.
 
obtained by using rifampicin as the drug (table 6). In such an experiment the EA
rosetting ability was also well correlated. The viable bacteria (green fluorescent)
containing macrophages in drug treated samples can be contrasted with number of
macrophages containing acid fast bacteria to show the loss of viability in the presence of
the drug since acid fast staining give total bacterial load and green fluorescent bacteria
indicate only viable among them.
 
 
Discussion
 
The earlier observation by Birdi et al. (1983), that live M. leprae, on entry into the
macrophages cultured in vitro from human peripheral blood, could reduce the number
of EA rosetting macrophages, has been found to be true with the peritoneal
macrophages from Swiss white mice. Like, in the human system, heat killed M. leprae
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Table 6. Correlation of viability of M. leprae as determined by flourescent diacetate method (FDA/EB)
with EA rosetting ability of macrophages and M. leprae in presence and absence of drugs.
 
*  0·2µg/tube 
**  0·5µg/tube     rifampicin 
 
could not do so. Birdi et al. (1984) had projected the usefulness of this system to screen 
drugs active against M. leprae by demonstrating the activity of rifampicin on M. leprae
using EA rosetting method with human macrophages. The data presented in this paper
show the adaptation of the method by a standardised procedure using macrophages
from mice and armadillo derived M. leprae. Entry of DDS into macrophages has been
clearly demonstrated and estimation of DDS inside the macrophages could also be
done. The concentration effect of DDS to inactivate the M. leprae was also indicated by 
the fact that DDS treated M. leprae did loose their viability which was further proven by 
the loss of their ability to pick up fluorescent labelling after treatment with fluorescent 
diacetate (Kvach, 1982). That the DDS is acting through the recognised pathway of a 
sulpha drug against M. leprae (Seydel, 1980) was further demonstrated by the partial 
reversal of DDS activity by PABA. Besides DDS, rifampicin a known anti M. leprae 
agent could also be shown to be active against M. leprae, ingested inside the 
macrophages, by the loss of their ability to pick up fluorescent labelling after treatment 
with fluorescent diacetate (Kvach, 1982). This was also shown by monitoring the ability 
of the bacteria to reduce the number of EA rosetting macrophages in the presence of the 
drug. 
Several clinically isolated M. leprae have been tested for drug sensitivity and 
resistance to DDS and rifampicin using this system. They are also being correlated with
behaviour of the isolates in mice foot pad (data not given).
Thus it is clear that by using macrophages and armadillo derived M. leprae, the drug
sensitivity of the bacteria to known and unknown drugs could be determined using the
EA rosetting ability of the macrophages. The test system can be completed in a period of
8–9 days, the shortest time needed in any of the test systems described so far (Vithala et 
al., 1983; Prasad et al., 1981; Nath et al., 1982) and quite similar to the one described 
from our earlier work using the cholesterol metabolism of the macrophages (Nair and 
Mahadevan, 1984). 
Several derivatives of methoxyindole have been tested using the method described
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here and some of them were found to be effective against M. leprae (data not given)
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